2023 World Conference on Lung Cancer (Posters)-EP11.03. Optimal Duration of Immune Checkpoint Inhbitors in Non-small Cell Lung Cancer: Less Is More?

EP11.03. Optimal Duration of Immune Checkpoint Inhbitors in Non-small Cell Lung Cancer: Less Is More? - PDF(Abstract)

Pdf Summary

A study was conducted to evaluate the optimal duration of immune checkpoint inhibitors (ICIs) in the treatment of non-small cell lung cancer (NSCLC). The study found that most patients who completed two years of ICI therapy maintained a response and achieved long-term survival. The study included 303 patients with advanced NSCLC who received ICI therapy, and only 19 patients completed two years of treatment without disease progression. These patients had received ICI monotherapy and none received combination therapy. After discontinuing ICI therapy, 31.6% of patients experienced disease progression, with a median time to progression of 16.8 months. Among the patients who progressed, 50% had achieved disease stabilization at 6 months, while 92.3% of patients without progression achieved a partial response. Four patients died due to tumor progression, with a median time to death of 6.8 months since disease progression. Only one patient was retreated with ICIs and achieved tumor stabilization. The median progression-free survival and overall survival have not been reached in the study. The findings support the hypothesis that two years could be an optimal duration for ICI therapy in NSCLC. Larger studies are needed to further investigate this and identify potential biomarkers to individualize treatment duration. The study provides valuable insights into the duration of ICI therapy in NSCLC and highlights the potential for long-term survival in these patients.

Asset Subtitle

Mariola Blanco Clemente

Meta Tag

Speaker Mariola Blanco Clemente

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immune checkpoint inhibitors

non-small cell lung cancer

NSCLC

optimal duration

treatment

response

long-term survival

disease progression

ICI monotherapy

combination therapy